Professional Documents
Culture Documents
Titer N (%)
< 0,5 BU 96/157 (61.1%)
(negative)
0,5 - <5 BU 50/157 (31.8%)
(low titer)
≥ 5 BU 11/157 (7%)
(high titer)
Characteristics
Blood. 2009;113:11-17
Risk factors
Severe hemophilia > mild or moderate hemophilia.
WFH
Children: every (first) 10-20 exposure
days or every 3-12 months.
Adult : as clinically indicated
Lack of response to adequate FVIII
infusion.
Before surgery
WFH, 2000
Management of acute bleeding
Normal Hemophilia
Blood.2004;104:3858-3864
TF independent mechanism of rFVIIa
rFVIIa
Facilitates hemostasis by activating factor X
directly on the platelet surface thereby
bypassing the tenase complex.
The half-life is 2.3 hours in adults but
potentially shorter in children
No potential for anamnesis to fVIII (small
amounts of fVIII can be found in PCCs/FEIBA )
rF VIIa Dose
Target joints :
A single dose of 270 mcg/kg or 3 doses of 90
mcg/kg
New drugs : re-balancing
hemostasis
Hematology 2006;421-5
In patient (pediatric ward, PICU)
Tahun No ID Diagnosis Clinical problems Treatment
Hemofilia A
Pseudotumor abdomen ec
1 JP berat, inhibitor rVIIa (Novo7) ke-1: 54 vial
hematoma abdomen, appendistis
titer tinggi
Burst abdomen, perdarahan luka
rVIIa ke-2: 136 vial
operasi
2017 Hemofilia A
Faktor VIII (Koate) 168 vial
Abd berat, inhibitor Perdarahan iliopsoas pro operasi
@500IU/vial, FEIBA
2 titer rendah
Hemofilia A
Faktor VIII (Koate) 82 vial
R berat, inhibitor Perdarahan intrakranial
@500IU/vial, CPA
3 titer tinggi
Hemoiflia A
berat, inhibitor Hyfema Novo7 30 vial
1 G titer tinggi
2015
Hemofilia A
berat, inhibitor Pseudotumor vesica urinaria Novo7 120 vial
2 MN titer tinggi
Transfusion-related infections
Handryastuti, Djajadiman G, Arwin AP Akib. Karakteristik klinis penderita hemofilia A dengan hemartrosis, 2002
Partiwi, Zuraida, Rulina S. Hepatitis C infection in hemophilia patients : prevalence and risk factors. Jakarta, 2000
Utilization of Cryoprecipitate vs
Factor VIII Concentrate
3.500.000
F VIII Concentrate
3.051.600
3.000.000 Cryoprecipitate
2.484.640
2.500.000
IU
2.293.600
2.000.000
1.500.000 1.249.200
1.213.360
1.000.000
500.000 572.400
488.400
201.600
0
2003 2004 2005 2006
Year
Prevalence of hepatitis C infection
in hemophilia A patients (n=72)
Transfusion period :
> 10 years 28 0
< 10 years 13 31
Cryoprecipitate
(mean) U/year 9123.9 5337.3
Partiwi, Zuraida, Rulina S. Hepatitis C infection in hemophilia patients : prevalence and risk factors. Jakarta, 2000
Correlation of donor screening and
HCV infection in hemophilia A patients (n=72)
Variabel Outcome Total
Anti HCV (+) Anti HCV (-)
Before screening 39 14 53
40% screening 2 7 9
100% screening 0 10 10
Total 41 31 72
Partiwi, Zuraida, Rulina S. Hepatitis C infection in hemophilia patients : prevalence and risk factors. Jakarta, 2000
OR = 0.1 (95%CI 0.01;0.65)
Transfusion-related infections